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Abstract: p16
Ink4a is a tumor suppressor and a marker for cellular senescence. Previous 
studies have shown that p16
Ink4a plays an important role in the response to DNA damage 
signals caused by telomere dysfunction. In this study, we crossed Wrn
−/− and p16
Ink4a−/− 
mice to knock out the p16
Ink4a function in a Wrn null background. Growth curves showed 
that loss of p16
Ink4a could rescue the growth barriers that are observed in Wrn
−/− mouse 
embryonic  fibroblasts  (MEFs).  By  challenging  the  MEFs  with  the  global  genotoxin 
doxorubicin, we showed that loss of p16
Ink4a did not dramatically affect the global DNA 
damage  response  of  Wrn
−/−  MEFs  induced  by  doxorubicin.  However,  in  response  to 
telomere dysfunction initiated by the telomere damaging protein TRF2
∆B∆M, loss of p16
Ink4a 
could partially overcome the DNA damage response by disabling p16
Ink4a up-regulation 
and reducing the accumulation of γ-H2AX that is observed in Wrn
−/− MEFs. Furthermore, 
in response to TRF2
∆B∆M overexpression, Wrn
−/− MEFs senesced within several passages. 
In  contrast,  p16
Ink4a−/−  and  p16
Ink4a−/−Wrn
−/−  MEFs  could  continuously  grow  and  lose 
expression of the exogenous TRF2
∆B∆M in their late passages. In summary, our data suggest 
that in the context of telomere dysfunction, loss of p16
Ink4a function could prevent cells 
from senescence. These results shed light on the anti-aging strategy through regulation of 
p16
Ink4a expression. 
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1. Introduction  
Extensive studies have demonstrated that telomere dysfunction could induce cellular senescence, 
ultimately  resulting  in  either  aging  or  cancer  [1–4].  Telomere  dysfunction,  including  telomere 
shortening due to a lack of telomerase function, telomere uncapping and structural damage due to 
defects in proteins maintaining telomere structure, could be recognized as a DNA damage signal that 
triggers the DNA damage response (DDR) in mammalian cells [5,6]. Depending on the intactness of 
the DDR system, for example, the status of the ATM-p53-p21 pathway, telomere dysfunction could 
either prevent or promote tumorigenesis [7–9].  
The role of the Rb-p16
Ink4a pathway in response to DNA damage induced by telomere dysfunction 
has  been  controversial.  p16
Ink4a  regulates  cell  cycle  progression  by  specifically  binding  to  and 
inhibiting the cyclin-dependent  kinases Cdk4 and Cdk6.  It  has  previously been demonstrated  that 
p16
Ink4a accumulates in conjunction with p38 activation in ras-induced senescent cells and that this 
accumulation is essential for senescence [10]. It has also been shown that p16
Ink4a accumulates in both 
human and mouse cells as a function of replicative senescence [11,12]. In a previous study, telomere 
dysfunction was induced by inhibiting the telomere binding protein TRF2 with the dominant negative 
protein TRF2
∆B∆M. This study demonstrated that the telomere damage induced by TRF2
∆B∆M induces 
p16
Ink4a  accumulation.  Inhibition  of  p16
Ink4a  with  shRNA  or  overexpression  of  BMI1  (a  p16
Ink4a 
transcription  regulator)  showed  a  nearly  complete  bypass  of  the  telomere-directed  senescence  in  
p53-deficient cells [13]. These data demonstrated that in human cells, p16
Ink4a plays an important role 
along with the p53 pathway in the DDR to telomere dysfunction. This same study demonstrated that in 
wild type MEFs, the loss of p53 function was sufficient to completely abrogate the senescence arrest, 
indicating that in the absence of p53, the loss of p16
Ink4a function is not necessary for mouse cells to 
bypass senescence [13]. In addition, previous studies have shown that inhibition of TRF2 results in 
apoptosis in MEFs and that this response is mediated by ATM and p53 [14]. 
Wrn,  a  member  of  the  RecQ  family  of  DNA  helicases,  is  deficient  in  patients  with  Werner 
syndrome (WS) [15]. WS is an autosomal recessive progeric disease that is characterized by premature 
atherosclerosis, ischemic heart disease, osteoporosis, and cataracts [16]. A previous study showed that 
inhibition  of  the  stress-induced  p38  MAP  kinase  could  prevent  the  senescence  of  WS  cells  [17]. 
Fibroblasts from WS patients have accelerated telomere erosion and senescence that can be rescued by 
the overexpression of telomerase, suggesting that telomere dysfunction may play an essential role in 
the manifestation of the WS phenotype [18]. To address this hypothesis, a mouse model of WS with a 
double knockout of mTerc and Wrn was generated, which faithfully manifested the human phenotype 
of  WS  [19,20].  The  Wrn  protein  is  necessary  for  efficient  replication  of  G-rich  telomeric  DNA, 
preventing telomere dysfunction and consequent genomic instability [21]. In addition, the function of 
Wrn in telomere regulation is regulated by TRF1 and TFR2 [22]. Thus, a mouse model deficient in 
Wrn function (Wrn
−/−) provides a very useful tool for investigating the factors involved in aging in 
response to telomere dysfunction. Int. J. Mol. Sci. 2012, 13  5868 
 
 
By crossing mice deficient in p16
Ink4a function (p16
Ink4a−/−) with mice deficient in Wrn function 
(Wrn
−/−), we generated mouse embryonic fibroblasts (MEFs) with the following genotypes: p16
Ink4a−/− 
only, Wrn
−/−only, and p16
Ink4a−/−Wrn
−/−. Furthermore, we challenged these cells with either the global 
genomic DNA damage reagent doxorubicin or the telomere specific damaging protein TRF2
∆B∆M. By 
comparing their growth rates, DDR, senescence status, and genomic instability, we investigated the 
role of p16
Ink4a in the induction of senescence by Wrn-related telomere dysfunction. 
2. Results and Discussion  
2.1. Loss of p16
Ink4a Function Overcame the Growth Barrier Caused by Dysfunction of Wrn 
To  investigate  the  growth  potential  of  MEFs  with  the  genotypes  p16
Ink4a−/−,  Wrn
−/−,  and 
p16
Ink4a−/−Wrn
−/−, we performed a growth curve analysis using wild type MEFs as a control. We found 
that  Wrn
−/−  MEFs  grew  slower  than  p16
Ink4a−/−  MEFs;  however,  knock  out  of  p16
Ink4a  function  
(p16
Ink4a−/−Wrn
−/−) rescued the growth potential of Wrn
−/− MEFs (Figure 1A). These data suggest that 
the  growth  barrier  caused  by  dysfunction  of  Wrn  is  overcome  by  the  loss  of  p16
Ink4a  function. 
Furthermore,  western  blot  analysis  revealed  that  compared  to  wild  type  MEFs  (Figure  1B,  WT), 
Wrn
−/− MEFs have dramatically increased p16
Ink4a expression (Figure 1B, Wrn
−/−). This result suggests 
that loss of Wrn function stimulates the expression of p16
Ink4a, which might cause the growth barrier of 
Wrn
−/− MEFs due to negative regulation of the cell cycle. Thus, knockout of p16
Ink4a function could 
overcome  the  growth  barrier  caused  by  a  defect  in  Wrn.  Surprisingly,  we  did  not  detect  an  
up-regulation of phosphorylated p53 in Wrn
−/− MEFs, suggesting that unlike doxorubicin treatment, 
the loss of Wrn did not cause sufficient DNA damage to stimulate the p53 pathway (Figure 1B, p-p53). 
In addition, p19
Arf, a response protein to oncogenic stimulation, did not show up-regulation in the 
absence of Wrn (Figure 1B, p19). Furthermore, we performed SA-β-Gal staining to detect cellular 
senescence in passage 13 of p16
Ink4a−/−, Wrn
−/−, and p16
Ink4a−/−Wrn
−/− MEFs. The results indicated that 
cellular senescence occurred in passage 13 of Wrn
−/− MEFs (57.31 ±  7.19% of cells were positive for 
SA-β-Gal  staining),  but  not  in  p16
Ink4a−/−  MEFs  (1.40  ±   0.53%  cells  were  positive  for  SA-β-Gal 
staining)  or  p16
Ink4a−/−Wrn
−/−  MEFs  (2.23  ±   1.86%  cells  were  positive  for  SA-β-Gal  staining)  
(Figure 1C). Int. J. Mol. Sci. 2012, 13  5869 
 
 
Figure 1. Wrn
−/− induced up-regulation of p16
Ink4a and caused a growth barrier in MEFs.  
(A)  Growth  curves  of  wild  type,  p16
Ink4a−/−,  Wrn
−/−  and  p16
Ink4a−/−Wrn
−/−  MEFs; 
(B) Western blot analysis of p16
Ink4a−/−, Wrn
−/− and p16
Ink4a−/−Wrn
−/− MEFs. Wild type 
MEFs (WT) with or without doxorubicin treatment were used as controls. (C) SA-β-Gal 
staining of p16
Ink4a−/−, Wrn
−/− and p16
Ink4a−/−Wrn
−/− MEFs at passage 13.  
 
2.2. DNA Damage Response to Genotoxin or Telomere Dysfunction in Cells Lacking Wrn or  
p16
Ink4a Function 
To further understand cellular senescence caused by telomere dysfunction in Werner syndrome and 
the role of Wrn and p16
Ink4a in the DNA damage response to telomere dysfunction, a well defined 
telomere  damaging  protein  TRF2
∆B∆M  [13]  was  introduced  into  p16
Ink4a−/−,  Wrn
−/−  and 
p16
Ink4a−/−Wrn
−/−  MEFs.  The global  genotoxin doxorubicin  was  used  in  parallel to  investigate the 
distinct stimulation of pathways involved in the DNA damage response.  
Western  blot  analysis  demonstrated  that  in  response  to  the  global  DNA  damage  caused  by 
doxorubicin, Chk2, p53, and H2AX proteins were phosphorylated in wild type, p16
Ink4a−/−, Wrn
−/− and 
p16
Ink4a−/−Wrn
−/− MEFs (Figure 2A, Chk2, p-p53, γ-H2AX). These data confirm that the regular DNA 
damage responses were stimulated in MEFs lacking Wrn or p16
Ink4a (Figure 2A, Wrn
−/−). Interestingly, 
in response to telomere dysfunction induced by the overexpression of TRF2
∆B∆M (Figure 2B, TRF2), 
Chk2 was not phosphorylated (Figure 2B, Chk2). In addition, no phosphorylated p53 could be detected 
(data not shown), suggesting a lack of response of Chk2-p53 to telomere dysfunction induced by 
TRF2
∆B∆M in the genetic context of these MEFs. However, p21 proteins were slightly up-regulated 
despite the p53 phosphorylation status (Figure 2B, p21). This result could be due to a p53-independent Int. J. Mol. Sci. 2012, 13  5870 
 
 
activation of p21 or a low level of p53 activation that is not detectable by western blot. H2AX proteins 
were phosphorylated significantly in response to TRF2
∆B∆M overexpression in wild type, p16
Ink4a−/−, 
Wrn
−/−, and p16
Ink4a−/−Wrn
−/− MEFs (Figure 2B, γ-H2AX), suggesting that TRF2
∆B∆M induces the 
activation of the DNA damage response. p16
Ink4a proteins were remarkably up-regulated in response to 
TRF2
∆B∆M overexpression in wild type MEFs, as well as Wrn
−/− MEFs (Figure 2B, p16). These data 
suggest that in p16
Ink4a−/− and p16
Ink4a−/−Wrn
−/− MEFs, the loss of p16
Ink4a function prevents cells from 
undergoing TRF2
∆B∆M-induced senescence. 
Figure 2. DNA damage response to genotoxin or telomere dysfunction in cells lacking 
either Wrn or p16
Ink4a function. (A) Western blot analysis to determine the response of 
MEFs to doxorubicin treatment; (B) Western blot analysis to determine the response of 
MEFs  to  TRF2
ΔBΔM  overexpression.  Wild  type  MEFs  (WT)  were  used  as  controls;  
(C)  SA-β-Gal  staining  of  p16
Ink4a−/−,  Wrn
−/−  and  p16
Ink4a−/−Wrn
−/−  MEFs  following 
TRF2
ΔBΔM overexpression. 
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Surprisingly, p19
Arf proteins were up-regulated in response to TRF2
ΔBΔM overexpression in wild 
type, p16
Ink4a−/−, Wrn
−/− and p16
Ink4a−/−Wrn
−/− MEFs (Figure 2B, p19), which was contrary to the 
response of MEFs to doxorubicin in which p19
Arf proteins were slightly down-regulated (Figure 2A, 
p19). These western blots were quantified (supplementary data 1). 
Interestingly, the background expression levels of the apoptotic marker Bax were up-regulated in 
p16
Ink4a−/−  and  p16
Ink4a−/−Wrn
−/−  MEFs,  but  not  in  Wrn
−/−  MEFs.  Upon  doxorubicin  treatment  or 
TRF2
ΔBΔM overexpression, Bax was not up-regulated (Figure 2A,B, Bax, actin was used as the loading 
control).  SA-β-Gal  staining  of  p16
Ink4a−/−,  Wrn
−/−  and  p16
Ink4a−/−Wrn
−/−  MEFs  after  TRF2
ΔBΔM 
overexpression showed  that  Wrn
−/− MEFs  senesced rapidly  after TRF2
ΔBΔM overexpression, while 
p16
Ink4a−/−Wrn
−/−  MEFs  did  not  appear  to  senesce  (Figure  2C).  These  data  further  support  the 
conclusion that loss of p16
Ink4a function prevents cells from TRF2
ΔBΔM-induced senescence. 
Telomere  dysfunction  could  induce  chromosomal  aberrations,  which  further  enhance  the 
destructiveness of telomere dysfunction, ultimately resulting in tumorigenesis. 
To investigate the chromosomal aberrations induced by TRF2
ΔBΔM overexpression in p16
Ink4a−/−, 
Wrn
−/− and p16
Ink4a−/−Wrn
−/− MEFs, we attempted to harvest chromosomes and perform cytogenetic 
analysis. However, TRF2
ΔBΔM overexpression leads to cellular senescence in wild type and Wrn
−/− 
MEFs, thereby preventing us from harvesting chromosomes from these cells for analysis. In contrast, 
despite the overexpression of TRF2
ΔBΔM, p16
Ink4a−/− and p16
Ink4a−/−Wrn
−/− MEFs continuously grow. 
We harvested the chromosomes from early passaged (p4), medium passaged (p18), and late passaged 
(p27) cells. Chromosome analysis (Table 1) showed that very few chromosomal breakages or fusions 
occurred in early and medium passages of MEFs, late passages of p16
Ink4a−/−Wrn
−/− MEFs that were 
overexpressing TRF2
ΔBΔM accumulated chromosomal fusions (12 of 30 cells in metaphase), and only a 
few fusions were found in late passages of p16
Ink4a−/− MEFs (2 of 30 cells in metaphase). We observed 
an increase of aneuploidy that correlated with increasing numbers of cell passages in both types of 
MEFs, which might be due to the cell passaging process itself. These data suggest that loss of p16
Ink4a 
function in a Wrn-deficient background rescues cellular senescence, but with the price of accumulating 
chromosomal aberrations. 
Table 1. Chromosome Analysis in MEFs overexpressing TRF2
ΔBΔM. 
MEFs’ Genotype 
metaphases 
counted 
breakage  fusion 
Diploid 
2N = 40 
Aneuploid 
2N > 40 
Aneuploid 
2N < 40 
p16
Ink4a−/− + TRF2
ΔBΔM-p4  30    1  15  14   
p16
Ink4a−/−Wrn
−/− + TRF2
ΔBΔM-p4  30      14  14  2 
p16
Ink4a−/− + TRF2
ΔBΔM-p18  30  1    7  20  2 
p16
Ink4a−/−Wrn
−/− + TRF2
ΔBΔM-p18  30      15  13  2 
p16
Ink4a−/− + TRF2
ΔBΔM-p27  30    2  1  27   
p16
Ink4a−/−Wrn
−/− + TRF2
ΔBΔM-p27  30    12  1  16   
2.3. Loss of p16
Ink4a Function Facilitated the Elimination of Exogenous TRF2
ΔBΔM in MEFs 
The  above  data  raise  the  question  of  how  p16
Ink4a−/−  and  p16
Ink4a−/−Wrn
−/−  MEFs  could 
continuously  grow  while  maintaining  the  overexpression  of  TRF2
ΔBΔM.  First,  we  confirmed  the 
overexpression of TRF2
ΔBΔM in early and medium passages of p16
Ink4a−/− and p16
Ink4a−/−Wrn
−/− MEFs Int. J. Mol. Sci. 2012, 13  5872 
 
 
using immunostaining. As expected, we could detect expression of TRF2
ΔBΔM in the nuclei of early 
passages (p4) of p16
Ink4a−/− and p16
Ink4a−/−Wrn
−/− MEFs (Figure 3A,B). However, in passage 18 of 
p16
Ink4a−/−  and  p16
Ink4a−/−Wrn
−/−  MEFs,  the  number  of  cells  with  positive  staining  for  TRF2
ΔBΔM 
decreased dramatically (Figure 3C,D).  
Figure 3. Overexpression of TRF2
ΔBΔM in early and medium passages of p16
Ink4a−/− and 
p16
Ink4a−/−Wrn
−/−  MEFs  revealed  by  immunostaining  (20×   and  40×   refer  to  the 
amplification power of the objective lens, DAPI was used to show the nuclear localization).  
(A) Early passage (P4) of p16
Ink4a−/− MEFs; (B) Early passage (P4) of p16
Ink4a−/−Wrn
−/− 
MEFs;  (C)  Late  passage  (P18)  of  p16
Ink4a−/−  MEFs;  (D)  Late  passage  (P18)  of 
p16
Ink4a−/−Wrn
−/− MEFs. 
 
The percentage of P4 p16
Ink4a−/− MEFs with positive staining for TRF2
ΔBΔM was around 45%, while 
positive staining of P18 p16
Ink4a−/− MEFs decreased to 20% (Figure 4A). Similarly, positive staining of Int. J. Mol. Sci. 2012, 13  5873 
 
 
P4 p16
Ink4a−/−Wrn
−/− MEFs was around 56%, while positive staining of P18 p16
Ink4a−/−Wrn
−/− MEFs 
decreased  to  39%  (Figure  4A).  Western  blotting  further  confirmed  the  decrease  of  TRF2
ΔBΔM 
expression in MEFs with the increasing cell passage number (Figure 4B, supplementary data 2). These 
data suggest that in the absence of p16
Ink4a, MEFs are able to lose expression of telomere dysfunction 
factors and, therefore, bypass senescence and sustain cell growth. 
Figure  4.  Elimination  of  TRF2
ΔBΔM  expression  in  the  late  passages  of  p16
Ink4a−/−  and 
p16
Ink4a−/−Wrn
−/− MEFs. (A) The percentage of cells positive for TRF2
ΔBΔM measured by 
immunostaining; (B)  Western blot showing  the decrease of  TRF2
ΔBΔM expression  with 
increasing cell passages. 
 
When the mouse model of Werner Syndrome (Wrn
−/−) was established by deleting a segment of the 
Wrn gene, the premature aging phenotype of human Werner Syndrome was not observed [23]. It is 
now  clear  that  this  observation  was  due  to  the  endogenous  telomerase  activity  in  mouse  somatic  
cells [19,20]. While Wrn
−/− mice display reduced embryonic survival, live-born mice appear normal 
during their first year of life. However, Wrn
−/− MEFs display a prematurely reduced growth rate as a 
function of passage number in culture, demonstrating that Wrn
−/− MEFs grow more slowly and have a 
lower saturation density in culture than their heterozygous and wild type counterparts [23].  
Using Wrn
−/− MEFs, we also observed the low growth potential of Wrn
−/− MEFs, which may be 
due to the up-regulation of the cell cycle inhibitor p16
Ink4a. Knockout of p16
Ink4a rescued the growth 
potential of Wrn
−/− MEFs, further supporting this point.  
Furthermore, the loss of either Wrn or p16
Ink4a function did not dramatically affect the cellular DNA 
damage response to the global genotoxin doxorubicin. However, when the dominant negative inhibitor 
of TRF2 (TRF2
ΔBΔM) was introduced into the cells and induced cellular senescence, the up-regulation 
response  of  p16
Ink4a  was  disabled  in  p16
Ink4a-deficient  cells,  which  resulted  in  distinct  cellular 
consequences between Wrn
−/− MEFs and p16
Ink4a−/−Wrn
−/− MEFs. In addition, the up-regulation of  
γ-H2AX in response to TRF2
ΔBΔM is reduced in p16
Ink4a−/−Wrn
−/− MEFs. Together these regulations in 
p16
Ink4a−/−Wrn
−/−  MEFs  overcame  the  cellular  senescence  induced  by  telomere  dysfunction  and Int. J. Mol. Sci. 2012, 13  5874 
 
 
sustained the continuous growth of cells with the consequence of the accumulation of chromosomal 
aberrations.  Eventually  p16
Ink4a−/−Wrn
−/−  MEFs  and  p16
Ink4a−/−  MEFs  could  lose  expression  of 
TRF2
ΔBΔM, which might further stabilize the chromosomes and stop the accumulation of chromosomal 
aberrations.  However,  we  found  that  in  p16
Ink4a−/−Wrn
−/−  MEFs  the  chromosomal  aberrations  still 
accumulated slowly due to the existing overexpression of TRF2
∆B∆M. In this case, the reduction of 
TRF2
∆B∆M levels slowed the accumulation of chromosomal aberrations. The mechanism responsible 
for  the loss of TRF2
∆B∆M expression  is not  clear; however, the loss of  p16
Ink4a  function played a 
permissive role in this process because the Wrn
−/− MEFs could not survive TRF2
∆B∆M overexpression.  
In contrast to a previous report [24], we did not observe p53 activation in response to TRF2
∆B∆M 
overexpression  in  these  MEFs.  A  previous  study  also  indicated  that  in  normal  human  epidermal 
keratinocytes, TRF2
∆B∆M overexpression caused only a two fold increase in both the phosphorylation 
of p53 at serine 15 and 53BP1 DNA damage foci and no detectable increase in p21. Despite the weak 
DNA damage response, the keratinocytes demonstrated growth arrest, reduced colony formation and 
senescence [25]. Another study demonstrated that uncapping telomeres with TRF2
∆B∆M resulted in 
apoptosis,  not  senescence.  These  authors  found  a  more  dramatic  activation  of  p53,  as  well  as  an  
up-regulation of Bax [14]. In our study, however, we did not observe activation of Chk2 or p53 or  
up-regulation of Bax. It is possible that a higher level of TRF2
∆B∆M results in apoptosis rather than 
senescence. It has also been shown that in human fibroblasts, telomere dysfunction induced senescence 
and signaled through ATM-p53-p21, but not p16
Ink4a, suggesting that distinct senescence programs 
could  progress  in  parallel,  resulting  in  mosaic  cultures  as  well  as  individual  cells  responding  to 
multiple signals [26]. 
Together,  these  data  suggest  different  roles  of  p53  and  p16
Ink4a  in  response  to  distinct  DNA 
damages and shed light on anti-aging strategies by the regulation p16
Ink4a expression. 
3. Experimental Section  
3.1. Cell Lines, Constructs and Antibodies 
MEFs  were  prepared  and  harvested  from  individual  day  13.5  mouse  embryos  from  designed 
parental mice with p16
Ink4+/− or Wrn
+/− genotypes (heterozygous knockouts of either p16
Ink4 or Wrn) 
and the harvested MEFs were cultured and genotyped. MEFs with wild type, p16
Ink4a−/−, Wrn
−/− or 
p16
Ink4a−/−Wrn
−/− genotypes were used for experiments. Wild type MEFs were used for experiments 
before passage 10 and the cells were passaged  at a ratio of 1:2 or 1:3 so that the cells were not 
excessively diluted and senesced too quickly. 
All  cell  lines  were  cultured  in  DMEM  medium  supplemented  with  10%  fetal  bovine  serum 
(Hyclone, CA, USA) in a 3% oxygen and 5% CO2 incubator at 37 ° C. 
The pBabe-TRF2
ΔBΔM (with a cMyc tag) construct, a gift from Dr. de Lange’s lab (as described  
in [27]), was introduced into MEFs. For transient transfection, cells were used 48 h after transfection. 
For stable expression, antibiotic selection was applied for 1–2 months and expression of TRF2
ΔBΔM 
was analyzed by both western blot and immunostaining.  
Antibodies  used  for  western  blot  were  anti-p16
Ink4a  (M-156)  (1:500,  Santa  Cruz,  CA,  USA),  
anti-Chk2 (1:500, BD Transduction Laboratories, CA, USA), anti-phospho-p53 (Ser15) (1:500, Cell Int. J. Mol. Sci. 2012, 13  5875 
 
 
Signaling, MA, USA), anti-cMyc (9E10) (1:500, Santa Cruz, CA, USA), anti-p19
Arf (1:1250, Upstate, 
NY, USA), anti-γ-H2AX (1:1000, Upstate, NY, USA), and anti-γ-tubulin (1:5000, Upstate, NY, USA). 
3.2. Growth Curve Assay 
A total of 2.5 ×  10
4 cells were seeded per well in 12 well plates and triplicates were prepared for 
each sample. At each time point, cells were fixed for 20 min at room temperature in 10% buffered 
formalin and stained with 1 mL 0.1% crystal violet for 20 min at room temperature. After the plates 
were washed and dried, cells were treated with 2 mL 10% acetic acid and the OD of the extracted dye 
was measured at 595 nm. Statistical analysis was performed to compare the difference between cell 
lines (n = 3). 
3.3. Immunostaining Assay 
Cells were fixed with 2% paraformaldehyde and 2% sucrose in 1×  PBS (pH 7.6) for 10 min and 
then permeabilized with 1% NP-40. After pre-incubation with 5% BSA/PBS, cells were incubated first 
with the primary antibody and then with the secondary antibody in 1% BSA/PBS for 1 h at room 
temperature.  After  DAPI  staining,  the  slides  were  mounted  with  ProLong  mounting  medium 
(Invitrogen,  CA,  USA).  Fluorescence  microscopy  was  performed  using  a  Nikon  Eclipse  90i 
fluorescence microscope and a Nikon Digital Sight CCD (controlled by NIS-Elements 3.0 software).  
3.4. SA-β-Gal Staining 
SA-β-Gal staining was performed as described previously [28]. Briefly, cultured cells were washed 
in 1×  PBS and fixed for 3–5 min (room temperature) in 2% formaldehyde, 0.2% glutaraldehyde. Fixed 
cells  were stained with  fresh  stain  solution  for SA-β-galactosidase  activity  at 37  ° C for 4 h.  The 
percentage of cells positive for SA-β-Gal staining were quantified and statistically analyzed (n = 3). 
4. Conclusions  
Our data suggest that, in the context of Wrn deficiency-related telomere dysfunction, loss of p16
Ink4a 
function could prevent cells from senescence. These results shed light on the anti-aging strategy by 
regulation of p16
Ink4a expression. 
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